PT Brigit Biofarmaka Technologi Tbk (IDX:OBAT)
Indonesia · Delayed Price · Currency is IDR 242.00
0.00 (0.00%)
At close: Aug 12, 2026
IDX:OBAT Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 174,927 | 160,118 | 120,627 | 56,930 | 38,496 | 37,853 | |
Revenue Growth | 39.95% | 32.74% | 111.89% | 47.89% | 1.70% | - |
Cost of Revenue | 110,987 | 98,437 | 64,206 | 34,578 | 19,022 | 14,872 |
Gross Profit | 63,940 | 61,681 | 56,421 | 22,352 | 19,474 | 22,981 |
Selling, General & Admin | 32,662 | 28,761 | 18,532 | 7,751 | 5,752 | 4,498 |
Other Operating Expenses | 947.82 | 356.88 | 110.26 | 94.21 | 110.23 | 188.84 |
Operating Expenses | 33,610 | 29,118 | 18,643 | 7,845 | 5,862 | 4,687 |
Operating Income | 30,331 | 32,563 | 37,778 | 14,507 | 13,611 | 18,294 |
Interest Expense | -1,962 | -1,832 | -1,381 | -1,253 | -845.28 | -279.34 |
Interest & Investment Income | 1,581 | 1,509 | 2,674 | 1,822 | 1,369 | 750.66 |
Earnings From Equity Investments | 312.69 | 495 | 406.25 | -250.26 | - | - |
Other Non Operating Income (Expenses) | 365.32 | 117.57 | 52.54 | -1.45 | -2.61 | 1.74 |
EBT Excluding Unusual Items | 30,628 | 32,852 | 39,531 | 14,824 | 14,133 | 18,767 |
Asset Writedown | -0.33 | - | -3.83 | -66.98 | -2.97 | -7.76 |
Other Unusual Items | - | - | - | 337.11 | 816.75 | 731.4 |
Pretax Income | 30,628 | 32,852 | 39,527 | 15,094 | 14,946 | 19,491 |
Income Tax Expense | 7,270 | 7,270 | 9,028 | 3,186 | 3,322 | 4,184 |
Earnings From Continuing Operations | 23,358 | 25,582 | 30,499 | 11,908 | 11,625 | 15,307 |
Minority Interest in Earnings | -4,513 | -2,940 | -1,073 | 65.94 | 759.76 | 342.69 |
Net Income | 18,845 | 22,642 | 29,426 | 11,974 | 12,384 | 15,649 |
Net Income to Common | 18,845 | 22,642 | 29,426 | 11,974 | 12,384 | 15,649 |
Net Income Growth | -38.48% | -23.05% | 145.75% | -3.32% | -20.86% | - |
Shares Outstanding (Basic) | 600 | 600 | 600 | 430 | 463 | 463 |
Shares Outstanding (Diluted) | 600 | 600 | 600 | 430 | 463 | 463 |
Shares Change | - | - | 39.53% | -7.13% | - | - |
EPS (Basic) | 31.41 | 37.74 | 49.04 | 27.85 | 26.75 | 33.80 |
EPS (Diluted) | 31.41 | 37.74 | 49.04 | 27.85 | 26.75 | 33.80 |
EPS Growth | -38.48% | -23.05% | 76.12% | 4.10% | -20.86% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3,747 | 3,204 | 6,355 | 6,528 | 7,148 | 14,908 |
Free Cash Flow Per Share | 6.25 | 5.34 | 10.59 | 15.18 | 15.44 | 32.20 |
Dividend Per Share | - | - | 22.370 | 16.950 | 32.400 | 17.280 |
Dividend Growth | - | - | 31.98% | -47.69% | 87.50% | - |
Gross Margin | 36.55% | 38.52% | 46.77% | 39.26% | 50.59% | 60.71% |
Operating Margin | 17.34% | 20.34% | 31.32% | 25.48% | 35.36% | 48.33% |
Profit Margin | 10.77% | 14.14% | 24.39% | 21.03% | 32.17% | 41.34% |
Free Cash Flow Margin | 2.14% | 2.00% | 5.27% | 11.47% | 18.57% | 39.38% |
EBITDA | 30,874 | 32,799 | 39,966 | 16,582 | 14,875 | 19,026 |
EBITDA Margin | 17.65% | 20.48% | 33.13% | 29.13% | 38.64% | 50.26% |
D&A For EBITDA | 543.98 | 236.81 | 2,188 | 2,075 | 1,263 | 731.94 |
EBIT | 30,331 | 32,563 | 37,778 | 14,507 | 13,611 | 18,294 |
EBIT Margin | 17.34% | 20.34% | 31.32% | 25.48% | 35.36% | 48.33% |
Effective Tax Rate | 23.74% | 22.13% | 22.84% | 21.11% | 22.23% | 21.47% |